{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:34:42Z","timestamp":1792784082324,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T00:00:00Z","timestamp":1555632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Taiwan Retina Society"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jfma.2019.04.012","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T13:34:26Z","timestamp":1557322466000},"page":"569-576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Management of polypoidal choroidal vasculopathy: Experts consensus in Taiwan"],"prefix":"10.1016","volume":"119","author":[{"given":"Lee-Jen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Kuo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiann-Torng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"San-Ni","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Kuo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Min","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Kuang","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hsiung","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenq-Lih","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-May","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Tien","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2019.04.012_bib1","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3390\/jcm4050782","article-title":"Polypoidal choroidal vasculopathy in Asians","volume":"4","author":"Wong","year":"2015","journal-title":"J Clin Med"},{"key":"10.1016\/j.jfma.2019.04.012_bib2","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","article-title":"Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management","volume":"125","author":"Cheung","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfma.2019.04.012_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","article-title":"Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians","volume":"53","author":"Wong","year":"2016","journal-title":"Prog Retin Eye Res"},{"issue":"8","key":"10.1016\/j.jfma.2019.04.012_bib4","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00417-018-4020-y","article-title":"A comparison of risk factors for age-related macular degeneration and polypoidal choroidal vasculopathy in Chinese patients","volume":"256","author":"Chen","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.jfma.2019.04.012_bib5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/08820538.2018.1506483","article-title":"Prevalence and risk factors for polypoidal choroidal vasculopathy in a general Japanese population: the hisayama study","volume":"33","author":"Fujiwara","year":"2018","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.jfma.2019.04.012_bib6","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3928\/15428877-20091030-07","article-title":"Polypoidal choroidal vasculopathy in Taiwanese patients","volume":"40","author":"Chang","year":"2009","journal-title":"Ophthal Surg Lasers Imag"},{"issue":"2","key":"10.1016\/j.jfma.2019.04.012_bib7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/IAE.0000000000001556","article-title":"Angiographic subtypes of polypoidal choroidal vasculopathy in Taiwan: a prospective multicenter study","volume":"38","author":"Yeung","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.jfma.2019.04.012_bib8","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/IAE.0b013e3182852446","article-title":"Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment","volume":"33","author":"Koh","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.jfma.2019.04.012_bib9","first-page":"417","article-title":"Criteria for diagnosis of polypoidal choroidal vasculopathy","volume":"109","author":"Japanese Study Group of Polypoidal Choroidal","year":"2005","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"10.1016\/j.jfma.2019.04.012_bib10","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.ajo.2014.08.025","article-title":"Sensitivity and specificity of spectral-domain optical coherence tomography in detecting idiopathic polypoidal choroidal vasculopathy","volume":"158","author":"De Salvo","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfma.2019.04.012_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ajo.2018.05.005","article-title":"Color fundus photography, optical coherence tomography, and fluorescein angiography in diagnosing polypoidal choroidal vasculopathy","volume":"192","author":"Chaikitmongkol","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfma.2019.04.012_bib12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3341\/kjo.2016.30.3.198","article-title":"Optical coherence tomography-based diagnosis of polypoidal choroidal vasculopathy in Korean patients","volume":"30","author":"Chang","year":"2016","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.jfma.2019.04.012_bib13","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/IAE.0000000000000794","article-title":"Distinguishing polypoidal choroidal vasculopathy from typical neovascular age-related macular degeneration based on spectral domain optical coherence tomography","volume":"36","author":"Liu","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.jfma.2019.04.012_bib14","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaophthalmol.2017.4360","article-title":"Optical coherence tomography angiography for assessment of the 3-dimensional structures of polypoidal choroidal vasculopathy","volume":"135","author":"Chi","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jfma.2019.04.012_bib15","first-page":"1","article-title":"Improved detection and diagnosis of polypoidal choroidal vasculopathy using a combination of optical coherence tomography and optical coherence tomography angiography","volume":"0","author":"Cheung","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.jfma.2019.04.012_bib16","first-page":"1","article-title":"Sensitivity and specificity of detecting polypoidal choroidal vasculopathy with en face optical coherence tomography and optical coherence tomography angiography","volume":"0","author":"de Carlo","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.jfma.2019.04.012_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000481540","article-title":"Spectral-Domain optical coherence tomography angiography for the diagnosis and evaluation of polypoidal choroidal vasculopathy","volume":"239","author":"de Carlo","year":"2018","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jfma.2019.04.012_bib18","doi-asserted-by":"crossref","first-page":"3479695","DOI":"10.1155\/2017\/3479695","article-title":"Sensitivity, specificity, and limitations of optical coherence tomography angiography in diagnosis of polypoidal choroidal vasculopathy","volume":"2017","author":"Huang","year":"2017","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jfma.2019.04.012_bib19","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jfma.2011.09.021","article-title":"Assessment of quality of life among Taiwanese patients with visual impairment","volume":"111","author":"Lin","year":"2012","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2019.04.012_bib20","doi-asserted-by":"crossref","first-page":"e011504","DOI":"10.1136\/bmjopen-2016-011504","article-title":"How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review","volume":"6","author":"Taylor","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.jfma.2019.04.012_bib21","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/IAE.0b013e318276e096","article-title":"Adjusted retreatment of polypoidal choroidal vasculopathy after combination therapy: results at 3 years","volume":"33","author":"Jeon","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.jfma.2019.04.012_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/0974-620X.192263","article-title":"Combined argon laser photocoagulation and antivascular endothelial growth factor for management of macular polypoidal choroidal vasculopathy","volume":"9","author":"Sen","year":"2016","journal-title":"Oman J Ophthalmol"},{"key":"10.1016\/j.jfma.2019.04.012_bib23","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1097\/IAE.0000000000000499","article-title":"Three-year results of polypoidal choroidal vasculopathy treated with photodynamic therapy: retrospective study and systematic review","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.jfma.2019.04.012_bib24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/01.iae.0000233647.78726.46","article-title":"Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy","volume":"27","author":"Hirami","year":"2007","journal-title":"Retina"},{"key":"10.1016\/j.jfma.2019.04.012_bib25","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ajo.2006.12.024","article-title":"Microrips of the retinal pigment epithelium in polypoidal choroidal vasculopathy","volume":"143","author":"Musashi","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfma.2019.04.012_bib26","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","article-title":"Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial","volume":"135","author":"Koh","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jfma.2019.04.012_bib27","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial","volume":"136","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jfma.2019.04.012_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2019.02.027","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: 2-year results of the PLANET study","author":"Wong","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfma.2019.04.012_bib29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/eye.2011.324","article-title":"Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy","volume":"26","author":"Cho","year":"2012","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jfma.2019.04.012_bib30","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/IAE.0000000000002035","article-title":"Short-term efficacy of conbercept and ranibizumab for polypoidal choroidal vasculopathy","volume":"39","author":"Huang","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.jfma.2019.04.012_bib31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2147\/DDDT.S158368","article-title":"Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy","volume":"12","author":"Peng","year":"2018","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.jfma.2019.04.012_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1089\/jop.2015.0150","article-title":"Vision preservation in eyes of polypoidal choroidal vasculopathy with low-dose intravitreal triamcinolone acetonide","volume":"33","author":"Liang","year":"2017","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jfma.2019.04.012_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/jop.2009.0073","article-title":"Photodynamic therapy with or without intravitreal triamcinolone acetonide for symptomatic polypoidal choroidal vasculopathy","volume":"26","author":"Lai","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jfma.2019.04.012_bib34","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00417-012-2137-y","article-title":"Two-year outcome of photodynamic therapy combined with intravitreal injection of bevacizumab and triamcinolone acetonide for polypoidal choroidal vasculopathy","volume":"251","author":"Nakata","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfma.2019.04.012_bib35","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1136\/bjophthalmol-2014-305189","article-title":"Three-year visual outcome of photodynamic therapy plus intravitreal bevacizumab with or without subtenon triamcinolone acetonide injections for polypoidal choroidal vasculopathy","volume":"98","author":"Sakai","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfma.2019.04.012_bib36","first-page":"CD011599","article-title":"Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema","volume":"4","author":"Mehta","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jfma.2019.04.012_bib37","first-page":"1150","article-title":"Treatment guidelines for age-related macular degeneration","volume":"116","author":"Takahashi","year":"2012","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"10.1016\/j.jfma.2019.04.012_bib38","series-title":"Congress of the Asia-Pacific Vitreo-retina Society (APVRS); Dec 8 \u2013 10","article-title":"EVEREST II trial: 2-year result","author":"Koh","year":"2017"},{"key":"10.1016\/j.jfma.2019.04.012_bib39","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12886-015-0064-5","article-title":"Photodynamic therapy versus anti-vascular endothelial growth factor agents for polypoidal choroidal vasculopathy: a meta-analysis","volume":"15","author":"Yong","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jfma.2019.04.012_bib40","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ophtha.2013.12.037","article-title":"LAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy","volume":"121","author":"Oishi","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfma.2019.04.012_bib41","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1097\/IAE.0000000000000526","article-title":"Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: the fujisan study","volume":"35","author":"Gomi","year":"2015","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.jfma.2019.04.012_bib42","doi-asserted-by":"crossref","first-page":"e12840","DOI":"10.1111\/eci.12840","article-title":"Polypoidal choroidal vasculopathy treatment options: a meta-analysis","volume":"48","author":"Qian","year":"2018","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jfma.2019.04.012_bib43","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3341\/kjo.2016.30.4.272","article-title":"Intravitreal anti-vascular endothelial growth factor for treating polypoidal choroidal vasculopathy with grape-like polyp clusters","volume":"30","author":"Chang","year":"2016","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.jfma.2019.04.012_bib44","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","volume":"32","author":"Koh","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.jfma.2019.04.012_bib45","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","article-title":"Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration","volume":"36","author":"Kim","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.jfma.2019.04.012_bib46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12886-015-0026-y","article-title":"Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy","volume":"15","author":"Hikichi","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jfma.2019.04.012_bib47","series-title":"Asia-Pacific Vitero-retina Society congress; Dec 14-16","article-title":"Two different treat and extend dosing regimens of intravitreal afibercept for wAMD in Japanese patients: 96 Week results of the ALTAIR study","author":"Ohji","year":"2018"},{"key":"10.1016\/j.jfma.2019.04.012_bib48","first-page":"296","article-title":"Recommended guidelines for use of intravitreal aflibercept with a treat-and-extend regimen for the management of neovascular age-related macular degeneration in the asia-pacific region: report from a consensus panel","volume":"6","author":"Koh","year":"2017","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.jfma.2019.04.012_bib49","first-page":"379","article-title":"Impact of polyp regression on 2-year outcomes of intravitreal aflibercept injections: a treat-and-extend regimen for polypoidal choroidal vasculopathy","volume":"72","author":"Morizane-Hosokawa","year":"2018","journal-title":"Acta Med Okayama"},{"key":"10.1016\/j.jfma.2019.04.012_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197042","article-title":"Choroidal structure as a biomarker for visual acuity in intravitreal aflibercept therapy for polypoidal choroidal vasculopathy","volume":"13","author":"Asano","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2019.04.012_bib51","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/eye.2017.126","article-title":"Submacular hemorrhage and grape-like polyp clusters: factors associated with reactivation of the lesion in polypoidal choroidal vasculopathy","volume":"31","author":"Kim","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jfma.2019.04.012_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184058","article-title":"Comparison of clinical features and 3-month treatment response among three different choroidal thickness groups in polypoidal choroidal vasculopathy","volume":"12","author":"Kong","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2019.04.012_bib53","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011188","article-title":"Factors predicting 2-year treatment results of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good baseline visual acuity","volume":"97","author":"Mori","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jfma.2019.04.012_bib54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/bjophthalmol-2017-310448","article-title":"Six-year outcomes of antivascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy","volume":"102","author":"Hikichi","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.jfma.2019.04.012_bib55","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/bjophthalmol-2018-311963","article-title":"Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy","volume":"103","author":"Miyata","year":"2018","journal-title":"Br J Ophthalmol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664618308453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664618308453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:40:23Z","timestamp":1760539223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664618308453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0929664618308453"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2019.04.012","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of polypoidal choroidal vasculopathy: Experts consensus in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2019.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}